Good MorningStocks got a boost from the Federal Reserve on Wednesday when it released its policy statement. In the
statement, the FOMC says it will aggressively dial back its bond purchasing program because its dual mandate
of employment and inflation have been met. The FOMC is indicating three interest rate hikes by the end of 2022
which is in line with the market’s expectations. The risk now is that inflation won’t respond to the policy shift
and the FOMC will be forced to act even more aggressively than it is now indicating.
On the economic front, the November retail sales figures came in much weaker than expected and reflect the
rising problem of inflation. Retail sales came in at up 0.3% versus an expectation of up 0.5% but the data does
not account for the impacts of inflation. With CPI up 6.8% for the year, the volume of sales is actually down
with the difference in the Retail Sales data made up by higher prices. Featured: These "Penny Coins" Are Crushing Bitcoin... (MMP) 
|
Markets | | | A flip of the calendar to January 2022 could be all it takes for social media driven meme plays to come back in style. For meme lovers, a turnaround may be near. That’s because with two weeks left in the year, tax loss selling pressure exerted by bandwagon traders that jumped into volatile meme plays on the way down will soon subside. Read the Full Story |
|
From Our PartnersFormer Chicago Board Options Exchange trader Bryan Bottarelli reveals the tricks and tips he learned trading in the live pit of the Chicago Board Options Exchange in a one-of-a-kind manual: "5 Secret Trading Strategies to Win Every Day in the Market." | | Click Here to Get Your Free Guide |
|
Stocks | | | It’s difficult to envision a market where tech stocks become an afterthought, although we simply can’t predict how long the current weakness in the sector will last. That’s why investors with cash on the sidelines should consider putting some of that capital to work by adding tech companies with strong growth prospects Read the Full Story |
|
Stocks | | | It was as if equity markets gave a collective sigh of relief yesterday after the Federal Reserve signaled it would begin “aggressive” tapering of its asset purchase program, while also aiming for three interest rate hikes in 2022. Read the Full Story |
|
|
Markets | | | Shares of ABM Industries, Incorporated (NYSE: ABM) are down nearly 10% in the wake of the Q4 earnings report and there are more reasons than one. Ultimately, the news is good but was not well received by the market. Read the Full Story |
|
Markets | | | Stocks fell in afternoon trading on Wall Street Wednesday as investors wait to hear from the Federal Reserve after its last policy meeting of the year.
The S&P 500 index fell 0.2% as of 1:32 p.m. Eastern and is coming off of two days of losses. The Dow Jones Industrial Average fel... Read the Full Story |
|
From Our PartnersChris Rowe reveals his #1 pick for the incoming tech boom, and shares why next-gen tech stocks could outpace Qualcomm's 2,600% run-up... Amazon's 2,550% surge... even JDS Uniphase Corp. historic 28,894% return. | | Take a look. |
|
Politics | | | With inflation surging and unemployment falling, the Federal Reserve said Wednesday that it will shrink its support for the economy more quickly and expects to raise interest rates three times next year.
Fed Chair Jerome Powell said the U.S. economy is growing at a “robust pace” even ... Read the Full Story |
|
Politics | | | Enbridge Energy moved Wednesday to shift to federal court a Michigan lawsuit seeking shutdown of an oil pipeline that runs beneath a channel linking two of the Great Lakes.
The Canadian company argued that a 2019 lawsuit filed in a state court by Attorney General Dana Nessel should be... Read the Full Story |
|
Markets | | | The luxury fashion house Chanel has chosen Leena Nair, an industry outsider from India and longtime executive at Unilever, to be its new CEO.
Analysts say her hiring signals how the brand is accounting for changing consumer awareness of the industry’s environmental impact and the imp... Read the Full Story |
|
Markets | | | Greenpeace on Wednesday renewed calls against proposed deep-sea oil and gas exploration off southwest Greece, warning of “unbearable” consequences to endangered Mediterranean whales and dolphins.
Greenpeace Greece official Kostis Grimanis said the project should be scrapped before “it... Read the Full Story |
|
Markets | | | Personal financial management platform provider MoneyLion (NYSE: ML) stock has lost nearly (-70%) of its value from its 2021 peak. The fintech envisions building a digital private banks for the working middle class and focuses on marketing heavily to the Generation-Z demographic. With an easy to use... Read the Full Story |
|
The Early Bird Stock Of The Day Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. | | View Today's Stock Pick |
|
